- Jul 14
- 10 min read
Key Takeaways
|
Introduction
Cancer treatment in China has emerged as one of the most compelling options for international patients seeking world-class oncology care at a fraction of Western costs. With cutting-edge technologies such as CAR-T cell therapy, targeted immunotherapy, precision medicine, and access to hundreds of active clinical trials, China's top hospitals now rival the best cancer centers globally.
This guide covers everything a patient or family needs to know: available treatments, leading hospitals, costs, how to navigate the system as a foreign patient, and the practical steps to plan a medical journey — all in one place. Wherever it's useful, we've linked out to our deeper guides on specific treatments, cancer types, and country-specific logistics so you can go as deep as you need on any topic.
Why Consider Cancer Treatment in China
Several structural advantages make China a serious option for oncology care, regardless of where a patient is traveling from:
Cost efficiency: Treatment costs are typically 40–80% lower than equivalent care in the US, UK, Australia, or Canada.
Access to CAR-T and clinical trials: China leads globally in active CAR-T cell therapy trials, and in June 2026 became the first country to approve a CAR-T therapy for a solid tumor. Patients can access some therapies years before they reach other markets.
Domestic drug availability: China has approved domestic biosimilars and generic targeted therapies at significantly reduced cost.
An integrative medicine model: Traditional Chinese Medicine is clinically managed alongside conventional oncology care, offering evidence-informed supportive treatment rather than an alternative to it.
High patient volumes: China's top cancer centers treat more patients annually than most global institutions — volume that's directly correlated with surgical and procedural expertise.
Regional accessibility: For patients across the Asia-Pacific — including Southeast Asia, Australia, and New Zealand — flight times to China are often shorter than to Western treatment centers, on top of the cost savings. Patients from Canada, the US, and further afield typically find the savings alone justify the trip; see our country-specific guides for Australia, Canada, New Zealand, Singapore, and Saudi Arabia for market-specific access gaps, visas, and costs.
Cancer Treatment Options Available in China
China's oncology system blends modern molecular medicine with decades of clinical experience. Patients have access to a broad spectrum of treatments — for a full breakdown of procedures and costs beyond oncology, see our guide to top medical procedures available in China.
1. CAR-T Cell Therapy
CAR-T (Chimeric Antigen Receptor T-cell) therapy is one of the most advanced cancer immunotherapies available, and China is now one of its world leaders — the NMPA has approved multiple CAR-T products, and as of 2024 China had the highest number of active CAR-T clinical trials globally.
2. Immunotherapy
Immunotherapy uses drugs — PD-1/PD-L1 inhibitors such as pembrolizumab, nivolumab, sintilimab, and camrelizumab — to help the immune system identify and attack cancer cells. Domestically produced immunotherapy drugs make this treatment significantly more affordable in China, and it's commonly used for lung cancer, liver cancer, melanoma, gastric cancer, and more.
3. Targeted Therapy
Targeted therapy focuses on specific genetic mutations (e.g., EGFR, ALK, HER2, KRAS). China's hospitals routinely conduct comprehensive tumor genetic profiling (NGS) to identify the most effective targeted agents for each patient.
4. Precision Medicine & Genomic Profiling
Precision medicine involves designing a treatment plan based on the patient's tumor DNA. Next-Generation Sequencing (NGS) panels are routinely used in China's top cancer centers both to guide initial therapy selection and to monitor response over time.
5. Radiotherapy (IMRT, SBRT, Proton Therapy)
Modern radiotherapy modalities including IMRT, SBRT, and proton beam therapy are available. Proton therapy is available at Shanghai Proton and Heavy Ion Hospital, minimizing damage to surrounding healthy tissue for localized tumors.
6. Traditional Chinese Medicine (TCM) Integration
TCM is clinically integrated alongside conventional cancer treatments — managing side effects, improving quality of life, and supporting immune recovery. This integrative model is unique to the Chinese oncology system; our evidence-based TCM guide covers what's supported by clinical data and what's still considered supportive rather than curative.
Treatment Modality Summary
Treatment Modality | What It Does | Best Suited For |
Targeted Therapy | Attacks specific molecular markers on cancer cells | Solid tumors with identifiable mutations |
Immunotherapy / CAR-T | Reprograms or mobilizes immune cells to destroy cancer | Blood cancers; refractory solid tumors |
Precision Medicine | Customizes treatment based on tumor genetic profile | All cancer types; complex or rare cases |
Radiotherapy (IMRT/SBRT) | Delivers high-dose radiation with pinpoint accuracy | Localized tumors; post-surgery clean-up |
Traditional Chinese Medicine | Supports recovery, reduces side effects, improves QoL | Used alongside conventional treatments |
CAR-T Cell Therapy: A Closer Look
CAR-T is the single most-searched and most-requested treatment among ChinaCureLink patients, so it's worth its own section here — with links to our full disease-specific guides for anyone ready to go deeper.
Approved indications: relapsed/refractory B-cell lymphoma, multiple myeloma, ALL
Key providers: CAMS, Peking University Cancer Hospital, Shanghai Changhai Hospital
Estimated cost in China: approx. USD $100,000–$150,000, versus $400,000–$500,000+ for the product alone in the US (total US cost of care, including hospitalization and monitoring, frequently runs higher still)
For a full walkthrough of our CAR-T offering — including which hospitals we work with and what's included in a treatment package — see our complete CAR-T treatment guide. If you already know which product or diagnosis applies to you, these guides go deeper:
CAR-T therapy cost in China for lymphoma — exact pricing, package inclusions, and real patient timelines
CAR-T therapy in China for multiple myeloma — myeloma-specific protocols, cost breakdowns, and eligibility
Relapsed/refractory leukemia CAR-T therapy — leukemia-specific protocols and survival outcome data
Pediatric CAR-T eligibility and pediatric CAR-T cost guide — for families evaluating treatment for a child
FDA-approved CAR-T products compared and Yescarta vs. Kymriah vs. Carvykti — for patients weighing a US product against a China-based pathway
Is It Safe? Hospital Quality & Regulation
A fair question for anyone new to medical travel: how do you know a hospital in China meets the standard you'd expect at home?
Every hospital in the ChinaCureLink partner network is Grade 3A certified — China's highest hospital classification, reserved for institutions with the highest standards of care, research capacity, and patient volume. CAR-T products used at our partner hospitals are approved by the NMPA (China's National Medical Products Administration), the country's equivalent regulatory body to the FDA or TGA. This is your assurance of clinical standards before you commit to travel.
Top Cancer Hospitals in China
China's top cancer centers combine high patient volumes, active research programs, and multidisciplinary tumor boards. All hospitals listed below are within the ChinaCureLink partner network.
Hospital | City | Specialties | Notable Feature |
Beijing Union Medical College Hospital | Beijing | All major cancers | Leading research + MDT model |
Fudan University Shanghai Cancer Center | Shanghai | Breast, lung, GI cancers | Asia-Pacific top-ranked cancer center |
Shanghai Changhai Hospital | Shanghai | Prostate, pancreatic, hematology | Active clinical trials hub |
Sun Yat-sen University Cancer Center | Guangzhou | Nasopharyngeal, liver cancer | Largest cancer center in South China |
Peking University Cancer Hospital | Beijing | Stomach, lymphoma, lung | National-level oncology research |
Note: Sun Yat-sen University Cancer Center treats over 80,000 new cancer patients annually — one of the highest-volume cancer centers in Asia.
The 7-Step Patient Journey for Cancer Treatment in China
Accessing the right cancer care in China requires expertise, local relationships, and careful coordination. ChinaCureLink manages every step of your journey — from your first contact to post-treatment follow-up — so you never face the system alone. Our 7-step process guide covers this in full detail; here's the short version.
What to Prepare Before You Arrive
To accelerate your case review and first consultation, have the following ready:
Pathology reports and biopsy results (English or Chinese accepted)
Imaging studies — CT, MRI, PET scans with radiology reports
Current medications, allergies, and surgical history
Previous treatment summaries (chemotherapy, radiotherapy, prior surgery)
Genetic/genomic testing results (NGS panel, if available)
Don't have all documents ready? That's fine — our coordinators will guide you through what's needed based on your specific diagnosis during your free consultation. If you're planning your trip from scratch, our step-by-step guide on how to plan a successful medical trip to China is a good place to start.
Language & Communication Support
ChinaCureLink provides professional bilingual medical interpreters for all appointments. Our coordinators speak English, Bahasa, Tagalog, and other languages. Our hospital partners' international departments support English-speaking patients. You will never need to rely on a general translation app for a medical decision.
Financial Planning with ChinaCureLink
We provide a transparent cost estimate covering treatment, accommodation, logistics, and interpretation before you commit to travel. We also liaise with international insurance providers on your behalf and can advise on coverage documentation.
Who Is a Candidate?
Eligibility depends heavily on diagnosis, treatment history, and current health status — there's no single answer that applies across cancer types. As a general guide, candidates for advanced options like CAR-T typically have a confirmed diagnosis matching an approved indication, have relapsed after or not responded to standard treatment lines, and are in stable enough condition to travel and complete a multi-week treatment stay. Our pediatric CAR-T eligibility guide breaks this down in concrete, numeric terms for one specific pathway as an example of how detailed this assessment gets.
The most reliable way to know where you stand is a free case review — our clinical team looks at your actual pathology, treatment history, and current status rather than applying blanket rules.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
★★★★☆ Sarah Zhang · Canada· Jul 2024 · Verified “The interpreter during the video call was fantastic — super professional and answered all our questions clearly and quickly. The professor was also very patient and gave us detailed and honest guidance on our treatment options.” |
★★★★★ Andrew Goh · Singapore · Aug 2024 · Verified “My first contact with Medebound was over a year ago. Jason has always been responsive, even when I wasn't ready to proceed. When I finally did, the consultation was seamlessly arranged and the specialist was outstanding.” |
★★★★★ Daniel Wong · Singapore · Aug 2024 · Verified “I have dry eye and nothing seemed to be working, even with different medications. I heard about a medication from the U.S. that’s supposed to be really effective, but I didn’t want to try it without talking to a doctor first. MEDEBOUND connected me with a top ophthalmologist in the U.S. and it was so reassuring to get their expert advice.” |
★★★★☆ Pongsakorn · Thailand · Feb 2025 · Verified “Kiki at Medebound is amazing — so professional and helpful! They got my video consultation with an MD Anderson expert set up super fast, within just 5 working days. I am so grateful for their support.” |
Frequently Asked Questions
What types of cancer treatment are available in China?
China offers a comprehensive range of oncology treatments including surgery, chemotherapy, radiotherapy (IMRT, proton), targeted therapy, immunotherapy (PD-1/PD-L1 inhibitors), CAR-T cell therapy, precision medicine based on genomic profiling, and integrative Traditional Chinese Medicine (TCM). Many top hospitals are also active clinical trial sites.
How much does cancer treatment in China cost for foreign patients?
Costs vary significantly by treatment type and hospital. Generally, cancer treatment in China costs 40–80% less than equivalent care in the US, UK, or Singapore. CAR-T cell therapy, which runs $400,000–$500,000+ in the US, is typically available for approximately $100,000–$150,000 in China. ChinaCureLink provides a detailed itemized estimate before you commit to travel.
Is CAR-T therapy available in China for international patients?
Yes. China is one of the global leaders in CAR-T cell therapy, with multiple NMPA-approved products and the largest number of active CAR-T clinical trials in the world as of 2024. ChinaCureLink coordinates CAR-T access at Shanghai Changhai Hospital and Peking University Cancer Hospital — see our complete CAR-T guide for the full details, or contact us to assess your eligibility.
Do I need to speak Chinese to receive treatment in China?
No. ChinaCureLink provides bilingual medical interpreters for all appointments. Our coordinators speak English, Bahasa, Thai, and Tagalog, and our partner hospitals have dedicated international patient departments. You will never navigate a medical consultation without language support.
Can international patients access clinical trials in China?
Yes. Many of China's top cancer hospitals are active clinical trial sites, and international patients are often eligible. Our clinical team reviews your diagnosis and identifies open trials that match your profile — including CAR-T, bispecific antibodies, and novel targeted agents not yet available in other countries.
How do I choose the right hospital for my cancer type?
ChinaCureLink matches your diagnosis to the specialist institution in our 50+ partner network with the highest caseload for your cancer type. For example, Sun Yat-sen University Cancer Center is highly regarded for nasopharyngeal and liver cancer, while Fudan University Shanghai Cancer Center excels in breast and GI oncology.
References
China's NMPA Approves First CAR T-Cell Therapy for CLDN18.2+, HER2- Advanced Gastric/GEJ Adenocarcinoma — OncLive, 2026. https://www.onclive.com/view/china-s-nmpa-approves-first-car-t-cell-therapy-for-cldn18--2-her2-advanced-gastric-gej-adenocarcinoma
CARsgen Makes History as China Approves World's First CAR-T Therapy for Solid Tumors — Fierce Pharma, 2026. https://www.fiercepharma.com/pharma/carsgens-gastric-cancer-car-t-nabs-world-first-approval-china-checking-landmark-solid-tumor
Costs of Care During Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory B-Cell Lymphomas — JNCI Cancer Spectrum / PMC, 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11340641/
Improving Outcomes and Mitigating Costs Associated With CAR T-Cell Therapy — AJMC, 2026. https://www.ajmc.com/view/improving-outcomes-and-mitigating-costs-associated-with-car-t-cell-therapy
The Different Classification of Hospitals Impact on Medical Outcomes of Patients in China — PMC, 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9339675/
China's Domestic PD-1/PD-L1 Inhibitors Demanding Global Attention — ILCN.org (WCLC), 2021. https://www.ilcn.org/chinas-domestic-pd-1-pd-l1-inhibitors-demanding-global-attention/
Evaluation of Changes in Price, Volume and Expenditure of PD-1 Drugs Following Government Reimbursement Negotiation in China — Journal of Global Health, 2025. https://jogh.org/2025/jogh-15-04069
Flourish of Proton and Carbon Ion Radiotherapy in China — Frontiers in Oncology / PMC, 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC8882681/
Sun Yat-sen University Cancer Center — Wikipedia, 2026. https://en.wikipedia.org/wiki/Sun_Yat-sen_University_Cancer_Center
About ChinaCurelink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top 5 cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team that understands both the medical and cultural needs of Southeast Asian patients.
ChinaCureLink is proudly affiliated with Medebound HEALTH— an international medical concierge company headquartered in New York, specialized in securing premium second opinions from top US hospitals and specialists. With over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized as one of the leading patient access services across North America and the Asia Pacific, Medebound HEALTH brings the same standard of expert care coordination to every patient we serve.
Comments